Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.
Candid Therapeutics has raised $505.0M in total funding. The most recent round was Undisclosed. The last funding was announced in March 2026.
Candid Therapeutics's investors include Franklin Templeton, RA Capital Management, Qiming Venture Partners, Samsara BioCapital, Vivo Capital.
Candid Therapeutics is headquartered in San Diego, United States.
Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.
Candid Therapeutics is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Candid Therapeutics — Funding & Investors." VCBacked, March 2, 2026, https://www.vcbacked.co/company/candid-therapeutics. Accessed September 15, 2026.
VCBacked. (2026). Candid Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/candid-therapeutics
{{cite web |title=Candid Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/candid-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated